CNBC host Jim Cramer continues to pound the table on Eli Lilly’s (LLY) stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The host of the TV show “Mad Money” continues to be a cheerleader for LLY stock, saying repeatedly that the pharmaceutical giant is a Strong Buy as its share price continues to trade sideways. Most recently, Cramer referred to Eli Lilly’s stock as a “coiled spring” that’s ready to bounce higher.
“This thing is just a coiled spring when we get the new numbers,” said Cramer, referring to Eli Lilly’s upcoming financial results that are scheduled for release on Aug. 7. “This is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not kidding. That’s what happens with these stocks. You know, (LLY) stock went from $200 to $600, then went to $900,” added the TV host.
Treading Water
Despite Cramer’s enthusiasm, and bullish calls among leading Wall Street analysts, LLY stock has largely been treading water this year. So far in 2025, Eli Lilly’s share price has gained only 2%, trailing the 7% increase in the benchmark S&P 500 index.
The underperformance comes despite strong global sales of Eli Lilly’s blockbuster weight-loss medication called Zepbound. Analysts say the reasons for the stocks underperformance include high expectations, big capital expenditures to ramp-up production of Zepbound, growing competition in the weight-loss drug space, and threats by U.S. President Donald Trump to impose 200% tariffs on the pharma industry.
For his part, Cramer seems unphased by these issues, and says that Eli Lilly is more than its weight-loss drug. “There are many big studies coming down the pipe. A hypertension study, it’s going to be remarkable. There’s going to be heart failure, and there’s going to be Alzheimer’s study,” said Cramer on a recent show, adding of LLY stock, “How can you leave this one right here?”
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,002.88 implies 25.46% upside from current levels.
